Showing 2621-2630 of 5617 results for "".
- Lynch Regenerative Medicine Names General Counsel, CMOhttps://reachmd.com/news/lynch-regenerative-medicine-names-general-counsel-cmo/2485740/Lynch Regenerative Medicine (LRM), a regenerative medicine company focused on platelet-derived growth factor–based therapies, has named Madison Dini as General Counsel and Chad Lindemann as Chief Marketing Officer. According to the company, Dini will lead legal, compliance, and corporate g
- CORAL Trial Results on Nalbuphine ER for IPF-Associated Chronic Coughhttps://reachmd.com/news/coral-trial-nalbuphine-er-ipf-chronic-cough/2485652/In the phase 2b randomized, double-blind, placebo-controlled CORAL trial, investigators evaluated nalbuphine extended release (ER) for idiopathic pulmonary fibrosis (IPF)-a
- Advances in Nanomedicine: Overcoming Tumor Barriers for Enhanced Cancer Therapyhttps://reachmd.com/news/advances-in-nanomedicine-overcoming-tumor-barriers-for-enhanced-cancer-therapy/2485558/Advanced, stage-gated engineering reframes nanoparticle design as a sequential solution to systemic, stromal and cellular delivery barriers—improving tumor delivery while limiting off-target toxicity.
- Innovative Nanocarrier Strategies to Overcome Drug Resistance in Esophageal Cancerhttps://reachmd.com/news/innovative-nanocarrier-strategies-to-overcome-drug-resistance-in-esophageal-cancer/2485525/Spatial targeting of the NTRK2–MAPK signaling axis represents a proposed translational strategy to address EGFR-TKI resistance in esophageal squamous cell carcinoma by directing nanocarriers to resistant, signaling-defined tumor niches. Rather than relying on diffuse
- FDA Grants Nanotechnology Designation to Curiteva’s 3D-Printed PEEK Spinal Implantshttps://reachmd.com/news/fda-grants-nanotechnology-designation-to-curitevas-3d-printed-peek-spinal-implants/2485392/Curiteva has received a nanotechnology designation from the U.S. Food and Drug Administration (FDA) for its Inspire 3D Printed Trabecu
- Community-Based Asthma Interventions: Lessons from the Navajo Nationhttps://reachmd.com/news/community-based-asthma-interventions-lessons-from-the-navajo-nation/2485253/A recent study found that a community asthma program on the Navajo Nation increased pediatric asthma care‑seeking and awareness during the COVID‑19 pandemic. Program mo
- Revolutionizing Tuberculosis Treatment: Emerging Inhalable and Nanoformulation Delivery Systemshttps://reachmd.com/news/revolutionizing-tuberculosis-treatment-emerging-inhalable-and-nanoformulation-delivery-systems/2485180/Inhalable aerosols and nanoformulation platforms now promise improved lung deposition and reduced systemic toxicity for pulmonary tuberculosis therapies.
- Exploring Nanotechnology in Drug Delivery and Antimicrobial Applicationshttps://reachmd.com/news/exploring-nanotechnology-in-drug-delivery-and-antimicrobial-applications/2485119/APZE is an azathioprine-loaded, colon-targeted nanoparticle that improves colonic delivery and shifts azathioprine metabolism in ways that may offer safety advantages. In a preclinical comparison,
- Understanding Picky Eating in Children: Insights from Recent Narrative Reviewshttps://reachmd.com/news/understanding-picky-eating-in-children-insights-from-recent-narrative-reviews/2484890/A recent narrative review shows persistent picky eating can threaten growth and micronutrient status, reframing it as a substantive pediatric concern r
- Comparing LMWHs in Preventing DVT Post-ACLR: Enoxaparin vs Nadroparinhttps://reachmd.com/news/lmwhs-dvt-post-aclr-enoxaparin-nadroparin/2484679/In patients undergoing anterior cruciate ligament reconstruction (ACLR), nadroparin was associated with a lower rate of postoperative lower‑limb deep‑vein thrombosis (DVT) than enoxaparin in a single‑center retrospective cohort. In a